Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Inclusion Criteria: * Crohn's disease for ≥ 3 months on endoscopy and on histological exam * Inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapies * Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450 * An average daily stool frequency ≥ 4 points and/or an abdominal pain of ≥ 2 points * Has Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≥ 6 (or SES-CD ≥ 4 in participants with isolated ileal disease) Exclusion Criteria: * Has a diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic colitis, or has strictures with prestenotic dilatation requiring procedural intervention * Has extensive small bowel resection (\>100cm) or known diagnosis of short bowel syndrome, or requires total parenteral nutrition * Current stoma, ileal-anal pouch anastomosis, or fistula Other protocol-defined inclusion/exclusion criteria apply